Skip to main content

Day: March 4, 2026

NCS Multistage Holdings, Inc. Announces Fourth Quarter and Full Year 2025 Results

Fourth Quarter ResultsTotal revenues of $50.6 million, a 13% year-over-year improvement and exceeding the high end of prior guidance Operating income of $5.2 million increased 78% year-over-year, outpacing revenue growth Net income of $15.0 million ($5.34 per diluted share), including a net positive impact of $9.8 million related to the release of our deferred tax valuation allowance Adjusted EBITDA of $9.2 million, compared to $8.2 million in the fourth quarter of 2024 and exceeding the high end of prior guidance $36.7 million in cash and $7.6 million in debt as of December 31, 2025Full Year ResultsTotal revenues of $183.6 million, a 13% improvement over 2024 Operating income more than doubled to $10.5 million from $4.3 million in 2024 Net income of $23.7 million ($8.65 per diluted share), including a net positive impact of $11.5...

Continue reading

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

LEXINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2025. “The previous year was an important period of transition for the Company, during which we sharpened our strategic priorities,” said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer. “With that foundation in place, our attention is firmly on execution – advancing rinvatercept into a Phase 2 clinical trial in patients...

Continue reading

Bowman Reports Results for Fourth Quarter and Full Year 2025; Raises 2026 Guidance

RESTON, Va., March 04, 2026 (GLOBE NEWSWIRE) — Bowman Consulting Group Ltd. (NASDAQ: BWMN), a national engineering services and program management firm, today announced record financial results for the fourth quarter and full year ended December 31, 2025. The company also raised net service billing guidance for 2026. “We delivered a record year in 2025,” said Gary Bowman, founder and CEO of Bowman. “Our focus on execution, organic growth and strategic acquisition is evident in our results. With double-digit growth of organic net service revenue, more than 100 basis point increase in adjusted EBITDA margin, improved cash conversion and the completion of several consequential acquisitions, we entered 2026 with strong momentum in the business and confidence in our markets. We’re well positioned for another breakout year as we...

Continue reading

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Reaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026; Type A meeting with FDA expected to occur within 30 days On track to submit regulatory applications for Anaphylm in Canada and the EU in 2026 Extends revenue sharing agreement with RTW to June 30, 2027 Excluding one-time items, meets 2025 guidance for revenue and non-GAAP adjusted EBITDA loss Guides to end FY2026 with cash and cash equivalents of $70 million Company to host investment community conference call on March 5, 2026WARREN, N.J., March 04, 2026 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today reported financial results...

Continue reading

Grocery Outlet Holding Corp. Announces Fourth Quarter and Fiscal 2025 Financial Results

EMERYVILLE, Calif., March 04, 2026 (GLOBE NEWSWIRE) — Grocery Outlet Holding Corp. (NASDAQ: GO) (“Grocery Outlet,” the “Company,” “we” or “our”) today announced financial results for the fourth quarter and full fiscal year ended January 3, 2026, both of which contained one additional week (“53rd week”) versus the comparable prior periods. Additionally, the Company today announced a business optimization plan (the “Optimization Plan”) to improve operational execution, strengthen long-term profitability and increase cash flow generation. Highlights for Fourth Quarter Fiscal 2025 as compared to Fourth Quarter Fiscal 2024:Net sales increased by 10.7% to $1.22 billion, which includes $82.4 million from the 53rd week. Comparable store sales declined by 0.8% on a 13-week basis. Gross...

Continue reading

Iveco Group publishes its 2025 Annual Report

Turin, 4th March 2026. Iveco Group N.V. (EXM: IVG) filed today its 2025 Annual Report with the Netherlands Authority for the Financial Markets (AFM) in European Single Electronic Format (ESEF). The document (which includes the Sustainability Statement prepared in accordance with the Corporate Sustainability Reporting Directive on a voluntary basis) is available in the Investors section of the Iveco Group corporate website at www.ivecogroup.com. Iveco Group N.V. (EXM: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society. The seven brands are each a major force in its specific business: IVECO, a pioneering commercial vehicles brand that designs, manufactures, and markets heavy, medium, and light-duty trucks; FPT Industrial, a global leader in a vast array of advanced powertrain...

Continue reading

Kaldalón hf.: Annual General Meeting 26 March 2026

The Board of Directors of Kaldalón hf. hereby announces that the Annual General Meeting of the company will be held on Thursday, March 26, 2026, at 16:00 GMT. The meeting will be held at Reykjavík Natura, Nauthólsvegur 52, 101 Reykjavík. Enclosed is the agenda for the Annual General Meeting.  Meeting documents and further information concerning the meeting is available on the website kaldalon.is/adalfundur2026.AttachmentKaldalón hf. – Aðalfundarboð 2026

Continue reading

Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M

Company Initiates Regulatory Discussions with CDSCO; Plans 408-Patient Pivotal Study Targeting Standard-Risk Several Viral Infected Outpatients BOSTON, March 04, 2026 (GLOBE NEWSWIRE) — Bioxytran, Inc. (OTCQB: BIXT) today announced positive dose optimization results for its lead antiviral candidate, ProLectin-M, and provided an update on the Company’s planned Phase 3 registrational trial. The data, released March 2, 2026, were designed to establish the optimal dosing strategy and support advancement into a pivotal study intended to enable full regulatory approval. Phase 3 Registrational Trial Overview Bioxytran has entered regulatory discussions with the U.S. Food and Drug Administration (FDA) and India’s Central Drugs Standard Control Organization (India regulator) to finalize the design of a Phase 3 registrational trial. Planned...

Continue reading

Toll Brothers Announces New Luxury Home Community Coming Soon to Tomball, Texas

Toll Brothers at Oakhill Reserve offers luxury living with modern home designs and exceptional amenities near Houston TOMBALL, Texas, March 04, 2026 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced its newest Houston-area luxury home community, Toll Brothers at Oakhill Reserve is coming soon to Tomball, Texas. This new community will feature two collections of one- and two-story single-family homes with modern architectural designs, expansive home sites, and an array of onsite amenities. Site work is underway, and the community is expected to open for sale in spring 2026.Offering homes priced from the upper $300,000s, Toll Brothers at Oakhill Reserve will showcase the Foxtail Collection and the Longleaf Collection, with thoughtfully designed floor plans set on 45-...

Continue reading

Regency at Rockhill Ridge by Toll Brothers Now Open in Sellersville, Pennsylvania

New 55+ community offers low-maintenance living and luxury townhomes SELLERSVILLE, Pa., March 04, 2026 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced the grand opening of Regency at Rockhill Ridge, a new 55+ active-adult community in Bucks County, Pennsylvania. The Sales Center and model home are now open at 2 Oakwood Lane in Sellersville.Regency at Rockhill Ridge is an intimate community of just 72 carriage-style townhomes, offering low-maintenance living with lawn care and snow removal included. Each home features a first-floor primary bedroom suite, with townhomes offering approximately 1,920+ square feet of luxury living space. Homes are priced from the mid-$500,000s. “We are thrilled to introduce Regency at Rockhill Ridge to the Sellersville area,”...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.